Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.
Mustang Bio, Inc. (Nasdaq: MBIO) is a clinical-stage biopharmaceutical company developing cell therapies for difficult-to-treat cancers, and its news flow reflects both scientific progress and capital markets activity. The company focuses on CAR T-cell therapies and an HSV-1 oncolytic virus, with programs aimed at malignant glioma, recurrent glioblastoma (GBM), high-grade astrocytomas, and related brain tumors.
News about Mustang Bio often centers on pipeline milestones, including updates on MB-101, an IL13Rα2-targeted CAR T-cell therapy, and MB-108, an HSV-1 oncolytic virus. The company has reported U.S. Food and Drug Administration Orphan Drug Designations for MB-108 in malignant glioma and MB-101 in recurrent diffuse and anaplastic astrocytoma and glioblastoma. Mustang Bio also highlights the MB-109 regimen, which combines MB-101 and MB-108 to reshape the tumor microenvironment and potentially enhance CAR-T activity in recurrent GBM and high-grade astrocytomas.
Investors following MBIO news will also see listing and financing developments, such as reverse stock split announcements, Nasdaq compliance updates on minimum bid price and stockholders’ equity requirements, and details of public offerings and warrant exercises. These items provide context on Mustang Bio’s access to capital and its efforts to maintain its Nasdaq Capital Market listing.
This news page aggregates Mustang Bio’s press releases and related coverage, giving readers a single place to review regulatory designations, clinical trial updates, facility and operational changes, and securities offerings. For those tracking MBIO, revisiting this page can help monitor how Mustang Bio’s cell therapy programs and corporate actions evolve over time.
Mustang Bio has signed an exclusive license agreement with Leiden University Medical Centre for a first-in-class ex vivo lentiviral gene therapy targeting RAG1 severe combined immunodeficiency (RAG1-SCID). This therapy is currently in a Phase 1/2 clinical trial in Europe, with the first patient enrolled. The RAG1-SCID program has received Orphan Drug Designation by the European Medicines Agency. Mustang's ongoing development of lentiviral gene therapies aims to address significant unmet needs in treating SCID, which affects nearly 60% of cases.
Mustang Bio (NASDAQ: MBIO) announced interim Phase 1/2 data on MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, to be presented at the 63rd ASH Annual Meeting on December 11-14, 2021. The treatment showed an overall response rate of 94% and a complete response rate of 62% among the 16 patients studied. No dose-limiting toxicities were recorded. Additionally, a webinar is scheduled for December 16, 2021, to discuss the updated results and future plans regarding the therapy.
Mustang Bio, Inc. (NASDAQ: MBIO) has received a $2 million grant from the National Cancer Institute to support a Phase 1 clinical trial of MB-106, a CAR T cell therapy targeting B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The trial aims to assess the treatment's safety and efficacy. Additionally, Mustang has obtained Federalwide Assurance approval, ensuring compliance with U.S. regulations for human research protection. The funding and approvals represent significant steps in advancing Mustang's therapeutic offerings in hematologic cancers.
Mustang Bio, a clinical-stage biopharmaceutical company (NASDAQ: MBIO), announced its participation in Chardan’s Virtual 5th Annual Genetic Medicines Conference on October 5, 2021, at 8:00 a.m. ET. Manuel Litchman, M.D., President and CEO, and the leadership team will engage in a fireside chat, with a live webcast available on Mustang's Investor Relations page for 30 days post-event. Mustang focuses on cell and gene therapies targeting hematologic cancers, solid tumors, and rare genetic diseases, and is partnered with leading medical institutions for CAR T therapies and lentiviral gene therapy.
Mustang Bio (NASDAQ: MBIO) announced that Christine Brown, Ph.D. will present updated Phase 1 clinical data on MB-101 (IL13Rα2‐targeted CAR T cells) at two major cancer conferences in October 2021. The first presentation, titled 'CAR T Cells in Primary Brain Tumors', will take place on October 1, 2021, at the First Annual Conference on CNS Clinical Trials. The second presentation, 'Advancing CAR T Cell Therapy for Glioblastoma', is scheduled for October 25, 2021, at the AACR Virtual Special Conference on Brain Cancer. These presentations focus on innovative treatments for brain cancer.
Mustang Bio, Inc. (NASDAQ: MBIO), a biopharmaceutical company focused on cell and gene therapies, announced participation in three virtual investor conferences in September 2021. CEO Manuel Litchman will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, and the Cantor Global Healthcare Conference on September 27. Webcasts of the presentations will be available on Mustang's website for about 30 days after the events.
Mustang Bio (NASDAQ: MBIO) reported financial results for Q2 2021, highlighting continued progress in CAR T and gene therapies. Key achievements included a 93% overall response rate and 67% complete response rate for MB-106 in high-risk B-NHL and CLL.
The FDA accepted IND for MB-106, with the first patient enrollment expected soon. Mustang secured an exclusive license for innovative CAR T technology and received PRIME designation from the EMA for MB-107. The company reported cash equivalents of $130.9 million and a reduced net loss of $14.4 million, or $0.16 per share.
Mustang Bio, Inc. (NASDAQ: MBIO) has secured an exclusive license from Mayo Clinic for a cutting-edge technology aimed at advancing CAR T-cell therapy. This novel platform utilizes a two-step method to activate patient T cells in vivo, potentially transforming CAR T administration into an off-the-shelf treatment. Preclinical proof-of-concept is established, with further development set at Mayo Clinic. Mustang plans to file an Investigational New Drug (IND) application for a Phase 1 clinical trial once a lead construct is identified, aiming to enhance patient accessibility and reduce treatment costs.
Mustang Bio (NASDAQ: MBIO) announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to its lentiviral gene therapy MB-107 for treating X-linked severe combined immunodeficiency (XSCID) in infants. This milestone comes as Mustang prepares for a pivotal Phase 2 clinical trial. The therapy has previously received ATMP and Orphan Drug designations from the EMA and FDA. XSCID, a rare genetic disorder, severely compromises the immune system and affects approximately 1 in 225,000 births.
Mustang Bio, Inc. (NASDAQ: MBIO) announced it received a $300,000 tax incentive from the Massachusetts Life Sciences Center (MLSC) to create 20 new jobs in 2021, maintaining this headcount through 2025. The MLSC awarded $19.5 million in total to various life science companies. Mustang's CEO, Manuel Litchman, expressed gratitude for the award, noting its significance amid stiff competition. This funding will aid the company's advancement in gene and CAR T cell therapies, which aim to address hematologic cancers and rare genetic diseases.
FAQ
What is the current stock price of Mustang Bio (MBIO)?
What is the market cap of Mustang Bio (MBIO)?
